PIK3CA and breast cancer: In SOLAR-1, alpelisib significantly improved the mPFS when combined with fulvestrant in patients with phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA)-mutated, aromatase inhibitor-resistant BC [19].